Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy

Constance C. F. M. J. Baaten, Floor C.J.I. Moenen, Yvonne M. C. Henskens, Frauke Swieringa, Rick J. H. Wetzels, René van Oerle, Harry F. G. Heijnen, Hugo ten Cate, Graham P. Holloway, Erik A. M. Beckers, Johan W. M. Heemskerk, and Paola E. J. van der Meijden

Disclosures: Sources of funding Funding for this project was provided by the EHA-ISTH Research Fellowship granted by the European Hematology Association and the International Society of Thrombosis and Haemostasis to PvdM. FS is supported by the Alexander von Humboldt Foundation. Conflict of interest: HtC reports grants from Bayer and is a member of the advisory board of Bayer, Pfizer and Leo. The other authors declare no relevant conflicts of interest.

Contributions: CB performed experiments, analyzed data and wrote the paper; FS, RW, RO, HH, GH performed experiments and analyzed data; FM and EB recruited the patients; YH contributed analytical support; HtC drafted the paper; JH and PvdM designed and coordinated the research and wrote the paper. All authors have seen and approved the final manuscript.